InflaRx Announces Late-Breaking Oral Presentation of Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

(SeaPRwire) –   JENA, Germany, March 18, 2026 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm leading the development of anti-inflammatory therapies through targeting the complement system, today revealed an oral presentation scheduled for the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The event is set to take place from March 27 to 31, 2026, in Denver, Colorado. 

Camilla Chong, MD, Chief Medical Officer of InflaRx, said: “It is a privilege that our Phase 3 trial data for vilobelimab in pyoderma gangrenosum (PG) have been chosen for a late-breaking oral presentation at AAD. We are eager to share these key findings in PG with the dermatology community and discuss our development program focused on the role of C5a/C5aR inhibition in other chronic immuno-inflammatory conditions.”

AAD 2026 Late-Breaking Presentation Details
Title: Vilobelimab Therapy for Ulcerative Pyoderma Gangrenosum: Outcomes from a Multicenter, Randomized, Placebo-Controlled Phase 3 Trial

Session Type: Oral presentation
Presenter: Benjamin Kaffenberger, MD
Time: March 28, 2026, 2:24-2:36 PM MT
Location: Bellco Theatre 3

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical enterprise at the forefront of anti-inflammatory therapy development, utilizing its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a acts as a strong inflammatory mediator, contributing to the progression of numerous inflammatory disorders. The company’s lead program is izicopan (INF904), an orally delivered small-molecule inhibitor of C5a-induced signaling through the C5a receptor, which has exhibited promising pharmacokinetic/pharmacodynamic (PK/PD) properties and therapeutic potential in Phase 1 and Phase 2a clinical trials. InflaRx is advancing izicopan for the treatment of several inflammatory conditions, including hidradenitis suppurativa (HS). Additionally, the Company has developed vilobelimab, a novel, first-in-class, intravenously administered anti-C5a monoclonal antibody that selectively binds to free C5a and has shown disease-modifying clinical efficacy and tolerability across multiple clinical studies.

Established in 2007, the InflaRx group maintains offices and subsidiaries in Jena and Munich, Germany, along with Ann Arbor, Michigan, USA. For more details, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are fully owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President and Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements beyond those of historical fact qualify as forward-looking statements, often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. Forward-looking statements are present in various sections of this release and may encompass statements about our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors detailed under the headings “Risk factors” and “Cautionary statement regarding forward-looking statements” in our periodic filings with the SEC. These statements are only valid as of the date of this press release and involve known and unknown risks, uncertainties, and other significant factors that could lead to material differences between our actual results, performance, or achievements and any future results, performance, or achievements expressed or implied by the forward-looking statements. Considering these risks, uncertainties, and other factors, you should not place excessive reliance on these forward-looking statements, and we assume no responsibility to update them, even if new information emerges in the future, except as legally required.